Vacancies on the advisory committees for the Center for Drug Evaluation and Research remain a problem for FDA, despite overall improvement in vacancy rates among all agency advisory panels.
The advisory committee vacancy rate hit an all-time low of 14% at the end of fiscal year 2013, down from...